Ravulizumab

What is Ravulizumab

Ravulizumab is a long-acting intravenous monoclonal antibody, complement inhibitor indicated for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).

The recommended adult dosing regimen for PNH and aHUS consists of a loading dose followed by maintenance dose every 8 weeks, offering an advantage over eculizumab, which is dosed every 2 weeks. 

Brand Name

ULTOMIRIS

Indications

  • hemolytic-uremic syndrome
  • paroxysmal nocturnal hemoglobinuria (PNH)

Side Effects

  1. abdominal pain
  2. alopecia
  3. anemia
  4. anorexia
  5. antibody formation
  6. anxiety
  7. arthralgia
  8. back pain
  9. constipation
  10. cough
  11. diarrhea
  12. dizziness
  13. dyspnea
  14. fatigue
  15. fever
  16. headache
  17. hypertension
  18. hyperthermia
  19. hypokalemia
  20. hypotension
  21. infection
  22. infusion-related reactions
  23. intracranial bleeding
  24. iron deficiency
  25. lymphadenopathy
  26. meningococcal infection
  27. myalgia
  28. nausea
  29. peripheral edema
  30. pharyngitis
  31. rash
  32. rhinitis
  33. rhinorrhea
  34. vitamin D deficiency
  35. vomiting
  36. xerosis

Monitoring Parameters

  • hemoglobin/hematocrit
  • LDH
  • platelet count
  • serum creatinine

Contraindications

  • breast-feeding
  • children
  • hemolysis
  • infants
  • infection
  • meningococcal infection
  • pregnancy
  • thrombotic microangiopathy
  • vaccination

Interactions

There are no drug interactions associated with Ravulizumab products.

15585

Sign up to receive the trending updates and tons of Health Tips

Join SeekhealthZ and never miss the latest health information

15856
Scroll to Top